Related Experiment Video
Updated: Jul 20, 2026
06:47
Microfluidics in Assessing Platelet Function
Published on: November 8, 2024
QSAR study of antiplatelet agents.
Alan R Katritzky1, Liliana M Pacureanu, Svetoslav Slavov
1Center for Heterocyclic Compounds, Department of Chemistry, University of Florida, Gainesville, FL 32611, USA. katritzky@chem.ufl.edu
Bioorganic & Medicinal Chemistry
|September 2, 2006
Summary
Researchers developed quantitative structure-activity relationship (QSAR) models to predict the antiplatelet activity of benzoxazinone derivatives targeting factor Xa. Artificial neural network (ANN) models showed superior predictive ability over multilinear models.
Area of Science:
- Medicinal Chemistry
- Computational Chemistry
- Pharmacology
Background:
- Platelet aggregation is crucial in thrombosis.
- Factor Xa is a key enzyme in the coagulation cascade.
- Benzoxazinone derivatives are explored for antiplatelet properties.
Purpose of the Study:
- To develop and compare QSAR models for predicting antiplatelet activity.
- To identify key structural features influencing inhibitory activity against factor Xa.
- To establish a basis for designing novel antiplatelet agents.
Main Methods:
- Quantitative Structure-Activity Relationship (QSAR) methodology.
- Multilinear regression (Hansch-type) analysis.
- Artificial Neural Network (ANN) backpropagation modeling.
Main Results:
- Both multilinear and ANN models demonstrated good predictive ability.
- The ANN model exhibited superior predictive performance (R² = 0.909) compared to the multilinear model (R² = 0.821).
- The multilinear model provided insights into structural factors governing antiplatelet activity.
Conclusions:
- QSAR is a valuable tool for optimizing benzoxazinone derivatives as antiplatelet agents.
- ANN models offer enhanced predictive accuracy for this class of compounds.
- Further development can leverage these findings to design potent factor Xa inhibitors.
Related Concept Videos
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:28Structure-Activity Relationships and Drug Design
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence its...
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence its...
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:27Coronary Artery Disease V: Interprofessional Care
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...